Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes

NCT02948777 is registered in ClinicalTrials.gov with Marja-Riitta Taskinen as lead sponsor.

NCT NCT02948777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02948777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes
Lead sponsor
Marja-Riitta Taskinen
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2016
Completion date
June 30, 2018
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus